Status:
RECRUITING
Inflammatory and Glutamatergic Mechanisms of Sustained Threat in Adolescents With Depression
Lead Sponsor:
University of California, Los Angeles
Collaborating Sponsors:
University of Southern California
University of California, Irvine
Conditions:
Depression in Adolescence
Eligibility:
All Genders
14-21 years
Brief Summary
Despite the prevalence and significant public health concern over depression among adolescents, up to 40% of depressed adolescents do not respond to first-line antidepressants (herein termed treatment...
Detailed Description
Despite the prevalence and public health significance of depression, up to 40% of depressed adolescents do not respond to first-line antidepressants (i.e., serotonin selective reuptake inhibitors \[SS...
Eligibility Criteria
Inclusion
- DSM-V criteria for a depressive disorder
- All sexes and genders
- All ethnicities
- Ages 14-21
- Postpubertal (Tanner stage \> 3)
- No medications that will interfere with the study (including antidepressants, mood stabilizers, hormone supplements, steroids, etc.) for at least 2-6 weeks (depending on exact medication)
- Currently being seen by a clinician who will treat the participant with fluoxetine or escitalopram
- The ability to provide assent, understand, and complete all study procedures
- Caregiver consent (if applicable)
Exclusion
- Primary mental health diagnosis other than a depressive disorder according to DSM-V
- Any contraindications to MRI scanning, phlebotomy, or SSRI treatment
- Stimulant usage
- A concussion within the last 6 weeks or any lifetime concussion with loss of consciousness for at least 10 minutes
- Any inflammatory conditions or use of anti-inflammatory medications that may influence study findings
- Any major neurological or developmental disorders which could impact the participant's ability to comply with study procedure
- Meeting for current or lifetime criteria of mania or psychosis, diagnosis of bipolar disorder, or any substance use disorders
- First-degree relative with current, past, or suspected mania or psychosis
Key Trial Info
Start Date :
July 6 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 30 2028
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT05329441
Start Date
July 6 2023
End Date
April 30 2028
Last Update
May 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, Los Angeles
Los Angeles, California, United States, 90095